Dr. Megan Coylewright is a structural interventional cardiologist whose clinical practice includes minimally invasive options to treat congestive heart failure (through valve repair and replacement, including TAVR and TEER) and prevent stroke (LAAO and PFO closure). She is a frequent lecturer on technical and procedural topics as well as the intersection of health policy and patient-centred shared decision-making, and is known for her advocacy to broaden access to cardiovascular therapies in clinical trials for women and patients of colour. Dr. Coylewright serves leadership roles for device trials of aortic stenosis, left atrial appendage closure, and interatrial shunt therapies, among others. She is the co-principal investigator for one of the largest studies of heart teams. She completed her medical school, residency, and Master of Public Health training at Johns Hopkins and served as health disparities coordinator at the Baltimore City Public Health Department. Five years of cardiovascular training were spent at the Mayo Clinic in her home state of Minnesota.